A trial looking at everolimus and dovitinib for kidney cancer that has spread (DEVELOP)
Cancer type:
Status:
Phase:
This trial looked at the combination of everolimus and dovitinib for a type of kidney cancer (renal cell cancer) called clear cell cancer that has spread.
More about this trial
Everolimus is a type of biological therapy called an mTOR inhibitor. It stops a protein called mTOR from working properly. mTOR controls other proteins that trigger cancer cells to grow. By blocking mTOR, everolimus may help stop cancer growing.
Doctors often use everolimus to treat kidney cancer that has spread. But it doesn’t always work. Doctors want to find out if taking a drug called dovitinib at the same time will help it work better.
Dovitinib is a new drug and is a type of biological therapy called a tyrosine kinase inhibitor or TKI. TKIs block tyrosine kinase, which is a chemical messenger (an enzyme) that sends messages to tell cells to divide and grow. Blocking tyrosine kinase may stop cancer cells growing.
The aims of this trial were to find out
- The best dose of everolimus and dovitinib to use for clear cell kidney cancer that has spread
- More about the side effects
- How well this new combination of treatment works
Summary of results
Despite attempting to contact the trial team, we have not been able to have the results for this trial checked.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Prof Thomas Powles
Supported by
Experimental Cancer Medicine Centre (ECMC)
Novartis
Queen Mary University of London
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
